Angiogenesis is a critical component of neoplastic and chronic inflammatory disorders, but whether angiogenesis also occurs in inflammatory bowel disease (IBD) has yet to be established. We assessed mucosal vascularization, expression of endothelial ␣V␤3 integrin, angiogenic factors, and their bioactivity in Crohn's disease (CD) and ulcerative colitis (UC) mucosa. Methods: Mucosal endothelium was immunostained for CD31 and factor VIII and quantified by digital morphometry. ␣V␤3 expression was studied in vivo by confocal microscopy and in vitro by flow cytometric analysis of human intestinal microvascular endothelial cells (HIMECs). Vascular endothelial growth factor (VEGF), interleukin (IL)-8, and bFGF levels were measured in mucosal extracts and cells and angiogenic bioactivity shown by induction of HIMEC migration and the corneal and chorioallantoic membrane angiogenesis assays. Results: Microvessel density was increased in IBD mucosa. Endothelial ␣V␤3 was strongly expressed in IBD but only sporadically in normal mucosa and was up-regulated in HIMECs by VEGF, tumor necrosis factor ␣, and bFGF. IBD mucosal extracts induced a significantly higher degree of HIMEC migration than control mucosa, and this response was mostly dependent on IL-8 and less on basic fibroblast growth factor or vascular endothelial growth factor. Compared with normal mucosa, IBD mucosal extracts induced a potent angiogenic response in both the corneal and chorioallantoic membrane assays. Conclusions: These results provide morphological, phenotypic and functional evidence of potent angiogenic activity in both CD and UC mucosa, indicating that the local microvasculature undergoes an intense process of inflammation-dependent angiogenesis. Thus, angiogenesis appears to be an integral component of IBD pathogenesis, providing the practical and conceptual framework for anti-angiogenic therapies in IBD.
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Background & Aims:
Angiogenesis is a critical component of neoplastic and chronic inflammatory disorders, but whether angiogenesis also occurs in inflammatory bowel disease (IBD) has yet to be established. We assessed mucosal vascularization, expression of endothelial ␣V␤3 integrin, angiogenic factors, and their bioactivity in Crohn's disease (CD) and ulcerative colitis (UC) mucosa. Methods: Mucosal endothelium was immunostained for CD31 and factor VIII and quantified by digital morphometry. ␣V␤3 expression was studied in vivo by confocal microscopy and in vitro by flow cytometric analysis of human intestinal microvascular endothelial cells (HIMECs). Vascular endothelial growth factor (VEGF), interleukin (IL)-8, and bFGF levels were measured in mucosal extracts and cells and angiogenic bioactivity shown by induction of HIMEC migration and the corneal and chorioallantoic membrane angiogenesis assays. Results: Microvessel density was increased in IBD mucosa. Endothelial ␣V␤3 was strongly expressed in IBD but only sporadically in normal mucosa and was up-regulated in HIMECs by VEGF, tumor necrosis factor ␣, and bFGF. IBD mucosal extracts induced a significantly higher degree of HIMEC migration than control mucosa, and this response was mostly dependent on IL-8 and less on basic fibroblast growth factor or vascular endothelial growth factor. Compared with normal mucosa, IBD mucosal extracts induced a potent angiogenic response in both the corneal and chorioallantoic membrane assays. Conclusions: These results provide morphological, phenotypic and functional evidence of potent angiogenic activity in both CD and UC mucosa, indicating that the local microvasculature undergoes an intense process of inflammation-dependent angiogenesis. Thus, angiogenesis appears to be an integral component of IBD pathogenesis, providing the practical and conceptual framework for anti-angiogenic therapies in IBD.
A ngiogenesis, also termed neoangiogenesis, is the process of new capillary formation from preexisting vasculature in adult tissues. 1 Angiogenesis is a fundamental constituent of many complex biological processes, including growth, development, and repair. In the last 3 decades, angiogenesis has emerged as a phenomenon essential for the growth of tumors, and its inhibition has been hailed as a cornerstone of cancer therapy. 2 In reality, the importance of angiogenesis extends well beyond cancer biology and has been shown to be an integral component of nonneoplastic chronic inflammatory and autoimmune diseases as diverse as atherosclerosis, rheumatoid arthritis, diabetic retinopathy, psoriasis, airway inflammation, peptic ulcers, and Alzheimer's disease. [3] [4] [5] Growth of new blood vessels is intrinsic to inflammation and is associated with structural changes, including activation and proliferation of endothelial cells and capillary and venule remodeling, all of which result in an expansion of the tissue microvascular bed. 6 -8 A potential functional consequence of this expansion is the promotion of inflammation through various correlated mechanisms. First, influx of inflammatory cells may increase; second, there is an increased nutrient supply that keeps feeding a metabolically active immune process; and third, the activated endothelium contributes to the local production of cytokines, chemokines, and matrix metalloproteinases. 9, 10 Therefore, the anatomic expansion of the microvascular bed combined with its increased func-tional activation can foster further recruitment of inflammatory cells, and angiogenesis and inflammation may become chronically codependent processes. 6, 8, 10, 11 A prime example of the process of immune-driven angiogenesis is seen in rheumatoid arthritis in which neovascularization is one of the earliest histopathological findings and a key contributor to pannus formation, in addition to playing an active proinflammatory role by being a source of cytokines, chemokines, and proteases. 12 Similar phenomena are observed in psoriasis, 13 and in fact they are likely to occur in all chronic immunemediated inflammatory conditions, including Crohn's disease (CD) and ulcerative colitis (UC), the 2 major forms of inflammatory bowel disease (IBD). 14 Very recently, IBD has been listed among the several conditions characterized or caused by abnormal or excessive angiogenesis, 4 although detailed information about the angiogenic status in inflamed mucosa is essentially nonexisting. 15, 16 At present, only a handful of reports suggest the presence of an abnormal vascular bed in IBD tissue. Based on resin casting, the CD mucosal microvasculature displays an aberrant morphology, 17 whereas Doppler ultrasound shows increased vessel density in the inflamed bowel loops 18 and a recent histologic study indicates that vascularization in IBD is particularly prominent in areas of active inflammation. 19 However, direct evidence of vascular remodeling and functionally active angiogenesis in IBD is still missing. Therefore, the present study was designed to obtain objective and direct evidence of increased vascularization in IBD mucosa, show activation of the local microvasculature, assess the levels of angiogenic factors in the inflamed tissues, identify their cellular sources, and detect biologically active angiogenic activity in IBD mucosa.
Materials and Methods

Isolation and Culture of Human Intestinal Cells
Surgical specimens were used for isolation of human intestinal microvascular endothelial cells (HIMECs), human intestinal fibroblasts (HIFs), and lamina propria mononuclear cells (LPMCs). All specimens were of colonic origin, and cells were isolated and cultured as previously reported. 20 -23 Tissues were obtained from histologically normal large-bowel specimens from patients admitted for bowel resection because of malignant and nonmalignant conditions, including colon cancer, benign polyps, and diverticulosis. Involved and uninvolved CD and UC colonic tissues were also obtained. All diagnoses were confirmed by clinical, radiologic, endoscopic and histologic criteria. The study was approved by the Institutional Review Board of University Hospitals of Cleveland.
Immunostaining and Morphometric Analysis of Intestinal Microvasculature
Immunostaining was performed as previously described. 23 Briefly, paraffin-embedded intestinal sections of histologically normal control and IBD-involved mucosa or paired uninvolved colonic mucosa were cut at 3 m thickness, deparaffinized then hydrated, blocked for endogenous peroxidase using 3% H 2 O 2 /H 2 O, and subsequently subjected to microwave epitope enhancement by using a Dako Target retrieval solution (Dako, Carpenteria, CA) at pH 10.00. Incubation with a primary antibody cocktail containing anti-CD31 and anti-von Willebrand factor (Dako) was performed at 1:200 dilution for 30 minutes at room temperature. Detection was achieved by using a standard streptavidin-biotin system (Dako), and antigen localization was visualized with 3=-3-diamino benzidene (DAB; Sigma, St Louis, MO).
Computerized morphometric analysis was performed by using an international consensus method for quantification of angiogenesis. 24, 25 Briefly, stained colonic sections were scanned at low power (ϫ40) to detect the most vascularized area, after which at least 5 microphotographs at high (ϫ200) magnification were taken of the mucosa, defined as the area above the muscularis mucosae (ie, the lamina propria), as well as the submucosa, defined as the area between the muscularis mucosae and muscularis propria. The following parameters were obtained by using an Optronics Color digital camera (Olympus Corporation, Tokyo, Japan): (1) number of vessels/field (vascular density), (2) blood vessel total area/tissue section, (3) mean blood vessel area (in m 2 )/tissue section, and (4) larger diameter/ vessel. Quantitative analysis of data was performed by using Image Pro Plus (Media Cybernetics, Silver Spring, MD).
Integrin ␣v␤3 Expression by Mucosal Microvasculature
Staining, microscopy, and imaging were performed as previously reported 26 by using a Leica TCS-SP laser scanning confocal microscope (Leica, Heidelberg, Germany) equipped with 3 lasers and photodetectors that permit detection of 3 separate fluorochromes. Frozen sections of histologically normal control and IBD-involved and uninvolved colonic mucosa were fixed in cold acetone for 1 minute, blocked in Hanks' balanced salt solution containing 2% fetal bovine serum (30 minutes at 25°C), and stained with a monoclonal antibody directed to ␣v␤3 (Chemicon International, Temecula, CA; 1 g/mL), or a polyclonal anti-CD31 antibody (1:100) (Santa Cruz Biotecnology, Santa Cruz, CA), both in Hanks' balanced salt solution with 2% fetal bovine serum overnight at 4°C. After incubation, the slides were rinsed 3 times and incubated with either biotinylated goat antimouse IgG (for ␣v␤3) or Alexa 488 (green) conjugated antigoat IgG (1:1000) (Molecular Probes, Eugene, OR) for 1 hour at room temperature. The anti-␣v␤3-incubated sections were again rinsed 3 times and exposed to a solution of fluorescein isothiocyanate conjugated (FITC) streptavidin (1:500) for 15 minutes. All slides were rinsed 3 additional times, blotted, and cover slips placed by using Vectashield mounting medium containing 4=6-diamidino-2-phenylindole (Vector Labs, Inc, Burlingame, CA). The slides were sealed and stored at Ϫ20°C until examined by confocal microscopy. Quantification of ␣V␤3 integrin expression was performed on immunostained frozen sections by a semiquantitative method (scores from 0 to 3), as described by Vonlaufen et al. 27 Flow Cytometry Analysis of HIMEC Detection of HIMEC integrin ␣V␤3 expression was performed by flow cytometry as previously described. 26 Briefly, HIMECs were plated on plastic and starved for 48 hours and then exposed to 100 U/mL tumor necrosis factor ␣ (TNF-␣) 50 ng/mL of basic fibroblast growth factor (bFGF), or 50 ng/mL of vascular endothelial growth factor (VEGF). After 24 hours, HIMECs were quickly tripsinized, washed twice, and incubated with anti-␣V␤3 monoclonal or isotype control antibody for 30 minutes in ice, washed again, and incubated with a mouse secondary-fluorescein isothiocyanate conjugated (FITC) antibody. After additional washing, HIMECs were analyzed by flow cytometry. Samples were analyzed by quantitative flow cytometry by using a Coulter Epics XL Flow Cytometer (Beckman Coulter, Inc, Fullerton, CA). Each analysis was performed on at least 10,000 events. Quantification of ␣v␤3 expression was obtained by using the Winlist software program (Verity Software House, Topsham, ME).
In some experiments, vitronectin-grown HIMECs were incubated with 100 g/mL Vitaxin (Medimmune, Gaithersburg, MD), a humanized ␣V␤3 specific antibody, or with 500 g/mL of the ␣v␤3-blocking peptide RGDV, and then plated again on vitronectin-coated wells. HIMEC morphology was followed up by digital photography (Olympus), and, after 6 hours, adherent and nonadherent cells were collected, stained with propidium iodide, and apoptosis determined by flow cytometry. 28 
Measurement of Mucosal and Cell-Derived Angiogenic Factors
Endoscopic biopsies were collected from the mucosa of UC and CD patients with active and inactive disease and from normal mucosa of control subjects. Biopsies were homogenized and sonicated in protein-lyses buffer containing protease inhibitors. 29, 30 Samples were centrifuged at 900 ϫ g for 15 minutes; supernatants were collected, filter sterilized, their protein concentration measured (Bio-Rad Laboratories, Hercules, CA), and kept frozen until analysis. 31 For induction of angiogenic factor production by HIFs or HIMECs, cells were seeded in 24-well cluster plates at 5 ϫ 10 4 /well/mL of their respective medium and grown to subconfluence, when 100 U/mL TNF-␣ (R&D Systems, Minneapolis, MN) or fresh medium were added. After a 48-hour incubation period, the confluent monolayers were extensively washed and supernatants were harvested for storage at Ϫ20°C.
For induction of angiogenic factor production by LPMCs, 2 ϫ 10 6 /well/mL cells were left untreated or stimulated with lipopolysaccharide (LPS) (1 g/mL) or anti-CD3/CD28 (10 and 1 g/mL, respectively). After 48 hours, supernatants were collected and stored at Ϫ20°C until analysis. Interleukin (IL)-8, VEGF, and bFGF were measured in the supernatants by enzyme-linked immunosorbent assay (ELISA, R&D Systems), as previously reported. 32 Content of VEGF in mucosal extracts was assessed by Western blotting using a primary rabbit anti-VEGF antibody (Santa Cruz) and analyzed by densitometry.
HIMEC Chemotaxis Assay
Chemotaxis was assessed by using previously reported methods with some modifications. 23, 33 Briefly, fluorescenceblocked polycarbonate filters (8 m pore size; BD Bioscience, Franklin Lakes, NJ) were coated with human fibronectin (10 g/mL) for 1 hour at room temperature. By using a transwell system, 35 ϫ 10 4 HIMECs were plated in the upper chamber in MCDB-131 medium, while the lower chamber contained chemotaxis buffer with phorbol myristate acetate (PMA) (10 ng/mL), bFGF (50 ng/mL), or VEGF (50 ng/mL) as positive controls or increasing concentrations (0.01-0.1 g/mL) of control or IBD-derived mucosal extracts. In some wells, 25 g/mL of blocking antibodies against IL-8, bFGF, or VEGF or control antibody were added to the chemotaxis buffer, as well as 100 g/mL of Vitaxin or 500 g/mL of the ␣v␤3-blocking peptide RGDV. After 4 hours, buffer was removed from both chambers, and HIMECs migrated onto the lower surface of the porous membrane were washed twice in phosphate-buffered saline (PBS) and stained with calcein for 15 minutes at 37°C. Duplicates of migrated cells were observed with an inverted fluorescence microscope and counted in 6 random high-power (ϫ200) fields. Quantitative analysis of data was performed by using the Image Pro Plus software.
Corneal and Chick Chorioallantoic Membrane Embryo Angiogenesis Assays
The murine corneal angiogenesis model was performed as previously described 34 by using a protocol approved by the animal experimentation committee of the Catholic University of Rome. Briefly, a single corneal pocket was created in each eye by using a modified von Graefe cataract knife. Filter papers containing PBS, 50 ng/mL of VEGF, or 0.1 g of control or IBD mucosal extracts were prepared and placed in each corneal pocket, positioned 1.0 mm from the corneal limbus. After surgery, erythromycin ophthalmic ointment was applied to each eye. Corneal neovascularization was evaluated 6 days after surgery by fluorescence microscopy, when mice received an intracardiac injection of 500 g of the endothelial cell marker BS-1 lectin, conjugated to FITC (Vector Laboratories). Thirty minutes later, mice were sacrificed, and each eye was enucleated and fixed in 1% paraformaldehyde solution for 1 hour. Then, corneal hemispheres were prepared under the dissecting microscope, placed on glass slides, and analyzed by fluorescence microscopy. Six to 8 eyes were studied in each group.
The chick embryo chorioallantoic membrane (CAM) assay was performed as described. 35 Briefly, a 4-day-old shell-less CAM was plated in a petri dish at 37°C in a humidified incubator. On day 6, a 1-mm filter paper disk containing PBS, 50 ng/mL of VEGF, or 0.1 g of control or IBD mucosal extracts was plated on the yolk sac membrane. After 2 days, the vascularization was observed under a fiberoptic light source and photographed.
Statistical Analysis
Data were analyzed by Graphpad software (San Diego, CA) and expressed as mean Ϯ standard error of the mean. The analysis of variance followed by the appropriate post hoc test was used. Statistical significance was set at P Ͻ .05.
Results
Qualitative and Quantitative Evidence of Increased Vascularization in IBD Mucosa
To obtain objective evidence of whether mucosal vascularization is increased in IBD, we initially performed immunohistochemical staining of histologically normal control and active CD-and UC-involved colonic tissue with antibodies specifically recognizing surface CD31 and intracytoplasmic von Willebrand/factor VIII, 2 widely used endothelial markers. 24, 25 Normal colon showed sporadic thin vessels in the lamina propria and submucosa, whereas tissue involved by CD or UC contained numerous readily detectable dilated vessels in both the lamina propria and submucosa (Figure 1 ). The same sections were morphometrically analyzed by multiple parameters obtained with a computerized imaging system. 25 The microvascular density measured as total number of vessels/field, percentage section area, mean vessel area, and mean larger vessel diameter were all significantly (P Ͻ .05-.01) increased in the lamina propria of CD and UC compared with histologically normal control specimens (Figure 2 ). The same parameters were also increased in the submucosa of IBD compared with control specimens (not shown). When paired specimens of inflamed and noninflamed autologous IBD mucosa were analyzed, a significantly (P Ͻ .05) increased vascularization was detected in the inflamed segments, whereas no differences were found between uninvolved IBD and control mucosa (not shown).
Expression of the Angiogenesis-Associated Integrin ␣V␤3 in IBD Mucosa Microvasculature
Morphometric evidence of increased vascularization suggests that angiogenesis is present in both forms of IBD, but this must be confirmed by detection of integrins selectively expressed by proliferating endothelial cells. 36, 37 Among several integrins, ␣V␤3 is unique because this molecule is expressed exclusively by angiogenic endothelium. Resting endothelium does not display the integrin ␣V␤3, whose expression is indispensable for proliferation during angiogenesis. 37 Vessels were identified by CD31 staining (not shown), and, by using antibodies against ␣V␤3 (red) and a nuclear staining (4=,6-diamidino-2-phenylindole, blue), abundant ␣V␤3-positive endothelial cells were readily discernible in both CD and UC mucosa ( Figure 3A) . The integrin ␣V␤3 was barely detectable in the resting microvasculature of normal control mucosa and uninvolved IBD mucosa (not shown). To validate this visual assessment, a semiquantitative analysis was performed confirming a significant (P Ͻ .01) increase of ␣V␤3-expressing vessels in IBD compared with normal control mucosa ( Figure 3B ).
␣V␤3-Dependent Survival of HIMEC
In view of the detection of ␣V␤3-positive endothelial cells in both UC and CD mucosa, we investigated 2 functional aspects of this molecule that are critical to angiogenesis: first, its up-regulation by inflammatory and angiogenesis mediators and, second, its role in endothelial cell survival. A relatively high number of HIMECs expressed ␣V␤3 in vitro, but after exposure to TNF-␣, bFGF, and VEGF for 24 hours, the number of ␣V␤3-expressing cells further increased by 20%-30% ( Figure 4) . As previously stated, integrins like ␣V␤3 are vital to the neovascularization process, and their blockade induces endothelial cell apoptosis, an event on which several current anti-angiogenic strategies are based. 36, 37 To learn whether this was also true for mucosal endothelial cells, vitronectin-adherent HIMEC monolayers were treated with Vitaxin, an anti-␣V␤3-specific antibody, 38 or the ␣V␤3-binding peptide RGDV. Both Vitaxin and RGDV induced detachment and rounding of HIMECs ( Figure 5A ), a response indicating the induction of apoptosis that was confirmed by propidium iodide staining ( Figure 5B ). Adherent cells were not apoptotic and expressed very low levels (2%-5%) of ␣V␤3 (not shown). 
Presence and Cellular Source of Angiogenic Factors in IBD Mucosa
The increased vascularization we observed in actively inflamed IBD tissue suggested the presence of increased amounts of angiogenic factors in the affected mucosa. To substantiate this conclusion, extracts of control and IBD mucosa were obtained and their content of VEGF, IL-8, and bFGF quantified. As measured by Western blot and densitometric analysis, VEGF was physiologically present in normal mucosa and its amount was markedly (P Ͻ .01) enhanced in both CD and UC when normalized to ␤ actin ( Figure 6A ). IL-8 was present in minute amounts in normal mucosa but in remarkably (P Ͻ .01) larger amounts in both CD and UC mucosa ( Figure 6B) . bFGF was present in all tissues but also at significantly (P Ͻ .05) higher concentrations in CD and UC mucosa ( Figure 6B ). When all 3 angiogenic factors were evaluated in mucosal extracts of UC and CD patients with inactive disease, their levels were essentially equal to those present in normal control tissues and significantly lower (P Ͻ .05 for VEGF, P Ͻ .05-.01 for IL-8, and P Ͻ .05 for bFGF) than those found in actively inflamed tissues ( Figure 6A and C) .
Next, we looked for the origin of VEGF, IL-8, and bFGF in LPMCs, HIFs, and HIMECs as representative of immune and nonimmune cellular sources. Control LPMCs were stimulated with LPS to preferentially activate monocytic cells and anti-CD3/CD28 to activate T cells, and angiogenic factors were measured in the culture supernatants. Unstimulated LPMCs spontaneously produced both VEGF and bFGF, and their levels increased significantly (P Ͻ .05) after LPS but not anti-CD3/CD28 stimulation ( Figure 7A ). In contrast, stimulation by either LPS or anti-CD3/CD28 doubled (P Ͻ .05) the amount of IL-8 spontaneously produced by LPMCs (Figure 7A) . The capacity of HIFs to produce the same angiogenic factors was investigated by exposing these mesenchymal cells to medium alone or TNF-␣ to mimic what occurs in inflamed mucosa. Although at rather different levels, unstimulated HIFs physiologically produced VEGF and bFGF but not IL-8 ( Figure 7B ). TNF-␣ induced remarkably high levels of VEGF (P Ͻ .01) and IL-8 (P Ͻ .001) but failed to up-regulate bFGF production ( Figure 7B ). Finally, HIMECs produced negligible amounts of VEGF and bFGF, both resting or after TNF-␣ stimulation, whereas IL-8 production was substantial in unstimulated cultures and increased significantly (P Ͻ .001) on TNF-␣ exposure (not shown).
Functional Bioactivity of IBD Mucosal Extracts In Vitro and In Vivo
Because endothelial cell migration is integral to the process of angiogenesis, the bioactivity detected in IBD mucosa should induce migration of the resident microvessels. Therefore, an in vitro angiogenesis assay translating HIMEC migration was used. 39 By using PMA and bFGF as positive controls (Figure 8) , we quantified the number of HIMECs migrated through a porous membrane in response to mucosal extracts. Both CD and UC extracts were significantly (P Ͻ .05) more potent than control extracts and induced HIMEC transmigration in a dose-dependent fashion (Figure 8 ). In order to gain insight into which specific factors might be responsible for HIMEC migration, neutralizing antibodies against IL-8, bFGF, and VEGF were added to the mucosal extracts before transmigration. All antibodies significantly reduced HIMEC migration, but blockade of IL-8 resulted in greater (P Ͻ .01) inhibition of migration than did bFGF (P Ͻ .05) and VEGF (P Ͻ .05) blockade ( Figure 9A) . When Vitaxin or the ␣v␤3 blocking peptide RGDV was used, HIMEC angiogenesis was totally abolished ( Figure 9B ).
To further prove that the angiogenic activity found in IBD mucosa was biologically functional, we performed the mouse corneal and the CAM assays, 2 in vivo correlates of angiogenesis. Corneas implanted with filter paper impregnated with CD or UC mucosal extracts exhibited an impressive angiogenic response, which was substantially more intense than that observed in corneas implanted with control mucosal extracts ( Figure 10A ). No new blood vessels were generated in corneas treated with PBS-soaked papers. Overall, similar results were obtained when the same extracts were used to induce vascularization in the CAM assay ( Figure 10B ). 
Discussion
The results of this study show that the inflammatory tissue reaction of IBD includes, in addition to a classical immune component, an active process of angiogenesis. The microvascular changes associated with angiogenesis are key contributors to the tissue injury and remodeling process that inevitably accompanies chronic inflammation. 6, 8, 10, 11 In contrast to the well-documented existence of angiogenesis in several other forms of chronic inflammation, 3-5,12,13,40 -42 there have been only indirect clues that these structural changes occur in IBD mucosa. [17] [18] [19] [43] [44] [45] [46] More importantly, no objective evidence of angiogenesis has been so far shown and quantified in CD or UC tissue. Quantification of angiogenesis is obtained by direct imaging of vessels, a method essential to reveal disease-associated vascular abnormalities. Among various techniques, microscopic imaging is the most validated approach for quantification of vasculature in normal and pathological tissues. 24, 26 To gather information on the vascularization state in IBD mucosa, we performed complete morphometric analyses using several complementary parameters. 24, 26 Regardless of the parameter used, the results showed that vascularization is increased in both forms of IBD, in both the mucosa and submucosa layers. Of special interest is the observation that increased vascularization is present only in tissues involved by active inflammation, a finding compatible with the concept of immune-driven angiogenesis 7, 8, 10, 47, 48 and indicative of a direct codependency between angiogenesis and inflammation. 6, 8, 11 An immune-driven inflammatory response impacts on the surrounding microvasculature by inducing the expression of integrins, key molecules essential to the generation of new blood vessels. 36, 37, 49, 50 Angiogenic integrins are not found on resting vessels, but their expression is the hallmark of an angiogenic vessel, particularly ␣V␤3, characteristically present in endothelial cells undergoing active proliferation. 36, 37, 49, 50 The prototypical examples are various human malignancies, 27, 51 including colon carcinoma, whereas ␣V␤3 is absent from the normal surrounding microvasculature. 27 In addition, ␣V␤3 is also found in the angiogenic vasculature of chronically inflamed tissues like rheumatoid synovium and psoriatic skin. 36, 52, 53 Our results showing the presence of ␣V␤3-positive endothelial cells in both CD and UC are fully compatible with the previously mentioned reports and support the hypothesis that active angiogenesis occurs in IBD mucosa. Similarly, there are no Ki67-positive endothelial cells in normal human colon, whereas this nuclear proliferation marker is significantly up-regulated in IBD endothelium (S.D., unpublished observations, October 2005), further strengthening the notion of active angiogenesis in the inflamed gut.
Considering that the expression of ␣V␤3 by the mucosal microvasculature is most prominent in mucosa involved by active inflammation, it is reasonable to assume that this phenomenon is because of the exposure of the endothelium to the proinflammatory and proangiogenic milieu of the neighboring tissue. Our observations of ␣V␤3 upregulation in HIMEC cultures exposed to TNF-␣, VEGF, and bFGF, all of which are increased in IBD tissue, support the previously mentioned assumption and further suggest that proinflammatory and proangiogenic factors act in a complementary fashion. 50 The importance of ␣V␤3 expression goes far beyond its significance as an angiogenesis marker. In addition to being uniquely expressed by proliferating endothelium, it is absolutely essential to its survival. 36, 37, 49 In fact, blocking ␣V␤3 is an approach to selectively target angiogenic endothelial cells. 36,54 -57 When this approach was adopted in HIMEC cultures by exposing them to Vitaxin and RGDV peptide, cell detachment and apoptosis were promptly induced. These results recapitulate those described with vessels from a variety of tissues and disease states 9,36,54 -56 and suggest that the inflamed intestinal microcirculation is also susceptible to cell death as a way of inhibiting pathological angiogenesis, as done in malignant and autoimmune conditions.
That angiogenesis is a response to the combined effects of multiple stimulatory signals derived from the tissue microenvironment is well established. 48,50,58 -60 In face of the complex nature of IBD, a number of cells and soluble mediators can be expected to participate in immunemediated mucosal neovessel formation. Molecules with known proangiogenic activity have been studied in IBD in the context of epithelial injury and repair, inflammation, or immunoregulation, but not angiogenesis. 61, 62 We first assessed the levels of VEGF, IL-8, and bFGF, 3 major angiogenic factors, in mucosal extracts and all were markedly increased in both CD and UC. Next, we looked for the possible cellular sources of these mediators. When LPMCs were studied, we found that activated macrophages preferentially synthesize VEGF and bFGF, whereas both T-cells and macrophages are active producers of IL-8. In addition to immune cells, nonimmune cells are also a rich source of angiogenic factors, particularly mesenchymal cells. [63] [64] [65] Therefore, resident HIFs were cultured and their production of angiogenic molecules assessed under resting and inflammatory conditions. After TNF-␣ conditioning, HIFs released massive amounts of VEGF and IL-8, but not bFGF, implying a differential capacity of immune and nonimmune cells to promote angiogenesis. The differential capacity of diverse cell types in inducing neovessel formation was further substantiated by the results with HIMECs, showing that the mucosal microvascular cells dramatically up-regulate IL-8, but not VEGF and bFGF, production in response to proinflammatory signals such as TNF-␣.
To prove that the angiogenic factors detected in mucosal extracts and cell supernatants possessed biological activity, we initially performed an endothelial cell migration assay by using HIMECs representing resident endothelial cells. This is a widely used system to show angiogenic activity in malignant and inflammatory tissues. 29, 30, 66, 67 An augmented capacity to induce a dosedependent migration of HIMECs was found in both CD and UC mucosal extracts. All 3 angiogenic factors studied above were active in inducing migration but to different degrees, IL-8 being the most potent, followed by bFGF and VEGF. Based on these results with specific mucosal cell types, one could speculate that because LPMCs, HIFs, and HIMECs are all abundant sources of IL-8, all 3 cell types are active contributors to mucosal angiogenesis in IBD. It should be remembered, however, that it is difficult to extrapolate this interpretation to the in vivo situation where all cells actively interact, and that many other angiogenic factors are likely to be produced in the inflamed mucosa. 7, 50, 68 To complement the investigation of biological activity, we finally performed experiments by using the corneal and CAM angiogenic assays, 2 classical systems that show new blood vessel formation in vivo. 35 Obvious vascular growth was readily observed in both assays, definitively proving the existence of functional proangiogenic activity in IBD mucosa.
Angiogenesis can be viewed as a 2-edged weapon: on 1 side, it is beneficial in wound healing and repair, whereas on the other side, it promotes tissue damage in neoplastic and inflammatory disorders. The dichotomy of the 2 responses is because of the fact that in a healing process angiogenesis is tightly regulated and self-limited, whereas in cancer and chronic inflammation angiogenesis is progressive and uncontrolled. 4, 6, 8, 10 In fact, promoting angiogenesis in animal models of rheumatoid arthritis, lung inflammation, psoriasis, and atherosclerosis causes worsening of disease. 69 -72 This appears to be true also in experimental IBD, based on preliminary results with VEGF-gene transfer in dextran sodium sulfate colitis that show a dramatic worsening of inflammation (S.D., unpublished observations). Further supporting the role of angiogenesis in IBD pathogenesis is the preliminary report that VEGF polymorphisms are associated with susceptibility to human IBD. 73 Based on these observations, it seems logical that angiogenesis blockade could be beneficial in chronic inflammation, as documented in many other systems. 9,40,74 -81 Specific supporting evidence has been found using the IL-10 -deficient model of colitis, where we recently showed the therapeutic effect of targeting angiogenesis by integrin ␣V␤3 blockade. 82 In addition, some of the drugs effective in treatment of human IBD, such as infliximab and thalidomide, have potent antiangiogenic activity, implying that they also act through angiogenesis blockade. 83, 84 In conclusion, the results of this study show that angiogenesis is an integral component of IBD pathogenesis and provide the material and conceptual bases for considering antiangiogenic strategies for IBD therapy as currently being tested in other autoimmune disorders.
Targeting new blood vessel formation holds the promise of decreasing influx of immune cells, cutting nutrient supply to an active inflammatory process, and reducing production of inflammatory and proteolytic mediators, all of which will help interrupt the dependency of chronic mucosal inflammation on a pathologically expanded microvascular bed.
